摘要
目的探讨非小细胞肺癌(NSCLC)血清中趋化素的表达和临床意义。方法收集120例非小细胞肺癌和86例健康人血清样本,通过酶联免疫ELISA试剂盒检测血清中趋化素表达量,分析其与非小细胞肺癌的临床病理特征关系以及诊断价值和预后关系。结果血清中趋化素在NSCLC患血清中的表达显著高于健康人正常血清中的表达量(t=6.68,P<0.01);非小细胞肺癌患者血清中趋化素高表达与淋巴结转移、远端转移、疾病分期、吸烟史均具有显著相关性(t=4.783,P=0.0025<0.01;t=5.261,P=0.0013<0.01;t=4.527,P=0.0035<0.01;t=5.216,P=0.0023<0.01);ROC曲线分析AUC=0.8813(95%CI,0.7324-0.8979;P<0.001);灵敏性和特异性分别是60.7%和88.4%;血清中趋化素低表达和高表达组在中位总生存时间OS上的差异具有统计学意义(χ~2=8.408,P=0.0037<0.01)。结论血清中趋化素在非小细胞肺癌中是高表达的,可以作为非小细胞肺癌的新型生物标记物和诊断靶标。
Objective To investigate the expression and clinical significance of serumchemerin in non-small cell lung cancer ( NSCLC). Methods Serum specimens from 120 NSCLC patients and 86 healtliy controls were col-lected. The levels of serum chemerin were measured by sandwich enzymelinked immunosorbent association between the clinic-pathological characteristics, prognosis and diagnostic value and serum chemerin of patients were furtlier investigated. Results The level of serum chemerin was significantly higher in the NSCLC group than in the healthy controls ( t = 6.6 8, P 〈 0. 01 ) . The higher level of serum chemerin was significantly associated witli advanced lymph node metastasis, distant metastasis, TNM stage, and smoking history (t = 4. 783, P =0. 0025〈0.01 ; t= 5.26 1 % P= 0 .0 0 1 3 〈0 .0 1 ; t= 4 .5 2 7 , P = 0 .0 0 3 5 〈 0 .0 1 ; t = 5 .2 1 6 , P = 0 .0 0 2 3 〈 0 . 0 1 ) . The area under the ROC cure was 0. 8813 ( 95% CI, 0. 7324 - 0 . 8979 ; P 〈 0 . 0 0 1 ) , and the sensitivity and specificity was 60. 7% and 88. 4%. The low serum chemerin expression and high serum chemerin expression groups were statistical-ly significant in overall survival time(Х^2 = 8. 408 , P =0.0037 〈 0 . 0 1 ) . Conclusion The measurement of chemerinmay be a useful diagnostic and prognostic biomarlcer for NSCLC patients.
出处
《临床肺科杂志》
2018年第3期417-420,共4页
Journal of Clinical Pulmonary Medicine